nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—Auranofin—psoriatic arthritis	0.147	0.203	CbGbCtD
Erlotinib—CYP1B1—Dexamethasone—psoriatic arthritis	0.0889	0.123	CbGbCtD
Erlotinib—ALB—Prednisone—psoriatic arthritis	0.0467	0.0646	CbGbCtD
Erlotinib—ABCG2—Dexamethasone—psoriatic arthritis	0.0423	0.0585	CbGbCtD
Erlotinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0403	0.0557	CbGbCtD
Erlotinib—CYP1A1—Dexamethasone—psoriatic arthritis	0.039	0.054	CbGbCtD
Erlotinib—ABCG2—Methotrexate—psoriatic arthritis	0.034	0.047	CbGbCtD
Erlotinib—ABCB1—Betamethasone—psoriatic arthritis	0.0262	0.0362	CbGbCtD
Erlotinib—ABCB1—Prednisolone—psoriatic arthritis	0.0259	0.0358	CbGbCtD
Erlotinib—ABCB1—Prednisone—psoriatic arthritis	0.0244	0.0338	CbGbCtD
Erlotinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0241	0.0334	CbGbCtD
Erlotinib—CYP3A5—Dexamethasone—psoriatic arthritis	0.0234	0.0324	CbGbCtD
Erlotinib—ALB—Methotrexate—psoriatic arthritis	0.0234	0.0324	CbGbCtD
Erlotinib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0225	0.0312	CbGbCtD
Erlotinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0183	0.0253	CbGbCtD
Erlotinib—CYP3A4—Betamethasone—psoriatic arthritis	0.0157	0.0217	CbGbCtD
Erlotinib—CYP3A4—Prednisolone—psoriatic arthritis	0.0155	0.0214	CbGbCtD
Erlotinib—ABCB1—Dexamethasone—psoriatic arthritis	0.0152	0.0211	CbGbCtD
Erlotinib—CYP3A4—Prednisone—psoriatic arthritis	0.0146	0.0202	CbGbCtD
Erlotinib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0144	0.0199	CbGbCtD
Erlotinib—ABCB1—Methotrexate—psoriatic arthritis	0.0122	0.0169	CbGbCtD
Erlotinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00913	0.0126	CbGbCtD
Erlotinib—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.000459	0.00166	CcSEcCtD
Erlotinib—Myocardial infarction—Betamethasone—psoriatic arthritis	0.000459	0.00166	CcSEcCtD
Erlotinib—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.000459	0.00166	CcSEcCtD
Erlotinib—Myocardial infarction—Dexamethasone—psoriatic arthritis	0.000459	0.00166	CcSEcCtD
Erlotinib—Conjunctivitis—Dexamethasone—psoriatic arthritis	0.000455	0.00164	CcSEcCtD
Erlotinib—Conjunctivitis—Betamethasone—psoriatic arthritis	0.000455	0.00164	CcSEcCtD
Erlotinib—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.000455	0.00164	CcSEcCtD
Erlotinib—Cerebrovascular accident—Methotrexate—psoriatic arthritis	0.000452	0.00163	CcSEcCtD
Erlotinib—Arrhythmia—Prednisolone—psoriatic arthritis	0.00045	0.00162	CcSEcCtD
Erlotinib—Pancreatitis—Prednisone—psoriatic arthritis	0.000449	0.00162	CcSEcCtD
Erlotinib—Erythema—Prednisolone—psoriatic arthritis	0.000439	0.00158	CcSEcCtD
Erlotinib—Eye disorder—Methylprednisolone—psoriatic arthritis	0.000432	0.00156	CcSEcCtD
Erlotinib—Neutropenia—Prednisone—psoriatic arthritis	0.000428	0.00154	CcSEcCtD
Erlotinib—Haemoglobin—Betamethasone—psoriatic arthritis	0.000423	0.00153	CcSEcCtD
Erlotinib—Haemoglobin—Dexamethasone—psoriatic arthritis	0.000423	0.00153	CcSEcCtD
Erlotinib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000421	0.00152	CcSEcCtD
Erlotinib—Haemorrhage—Betamethasone—psoriatic arthritis	0.000421	0.00152	CcSEcCtD
Erlotinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000417	0.0015	CcSEcCtD
Erlotinib—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000414	0.00149	CcSEcCtD
Erlotinib—Weight decreased—Prednisone—psoriatic arthritis	0.000414	0.00149	CcSEcCtD
Erlotinib—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000413	0.00149	CcSEcCtD
Erlotinib—Depression—Prednisone—psoriatic arthritis	0.000407	0.00147	CcSEcCtD
Erlotinib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.000405	0.00146	CcSEcCtD
Erlotinib—Erythema—Triamcinolone—psoriatic arthritis	0.000404	0.00146	CcSEcCtD
Erlotinib—Erythema—Methylprednisolone—psoriatic arthritis	0.000403	0.00145	CcSEcCtD
Erlotinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000403	0.00145	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.000402	0.00145	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.0004	0.00144	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisone—psoriatic arthritis	0.0004	0.00144	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000399	0.00144	CcSEcCtD
Erlotinib—Syncope—Prednisolone—psoriatic arthritis	0.000394	0.00142	CcSEcCtD
Erlotinib—Eye disorder—Dexamethasone—psoriatic arthritis	0.000393	0.00142	CcSEcCtD
Erlotinib—Eye disorder—Betamethasone—psoriatic arthritis	0.000393	0.00142	CcSEcCtD
Erlotinib—Back pain—Triamcinolone—psoriatic arthritis	0.00039	0.00141	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisolone—psoriatic arthritis	0.000386	0.00139	CcSEcCtD
Erlotinib—Arrhythmia—Betamethasone—psoriatic arthritis	0.000376	0.00136	CcSEcCtD
Erlotinib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000376	0.00136	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—psoriatic arthritis	0.000375	0.00135	CcSEcCtD
Erlotinib—Alopecia—Dexamethasone—psoriatic arthritis	0.000372	0.00134	CcSEcCtD
Erlotinib—Alopecia—Betamethasone—psoriatic arthritis	0.000372	0.00134	CcSEcCtD
Erlotinib—Haemoglobin—Prednisone—psoriatic arthritis	0.000368	0.00133	CcSEcCtD
Erlotinib—Haemorrhage—Prednisone—psoriatic arthritis	0.000366	0.00132	CcSEcCtD
Erlotinib—Erythema—Betamethasone—psoriatic arthritis	0.000366	0.00132	CcSEcCtD
Erlotinib—Erythema—Dexamethasone—psoriatic arthritis	0.000366	0.00132	CcSEcCtD
Erlotinib—Syncope—Triamcinolone—psoriatic arthritis	0.000362	0.00131	CcSEcCtD
Erlotinib—Syncope—Methylprednisolone—psoriatic arthritis	0.000361	0.0013	CcSEcCtD
Erlotinib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.00036	0.0013	CcSEcCtD
Erlotinib—Oedema—Prednisolone—psoriatic arthritis	0.000358	0.00129	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—psoriatic arthritis	0.000358	0.00129	CcSEcCtD
Erlotinib—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000355	0.00128	CcSEcCtD
Erlotinib—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000354	0.00128	CcSEcCtD
Erlotinib—Shock—Prednisolone—psoriatic arthritis	0.000352	0.00127	CcSEcCtD
Erlotinib—Cough—Triamcinolone—psoriatic arthritis	0.000352	0.00127	CcSEcCtD
Erlotinib—Myalgia—Triamcinolone—psoriatic arthritis	0.000344	0.00124	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—psoriatic arthritis	0.000343	0.00124	CcSEcCtD
Erlotinib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000343	0.00124	CcSEcCtD
Erlotinib—Myalgia—Methylprednisolone—psoriatic arthritis	0.000343	0.00124	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—psoriatic arthritis	0.000342	0.00124	CcSEcCtD
Erlotinib—Anxiety—Methylprednisolone—psoriatic arthritis	0.000342	0.00123	CcSEcCtD
Erlotinib—Infestation—Methotrexate—psoriatic arthritis	0.000341	0.00123	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000341	0.00123	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00034	0.00123	CcSEcCtD
Erlotinib—Depression—Methotrexate—psoriatic arthritis	0.00034	0.00123	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000338	0.00122	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—psoriatic arthritis	0.000335	0.00121	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—psoriatic arthritis	0.000332	0.0012	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000332	0.0012	CcSEcCtD
Erlotinib—Oedema—Triamcinolone—psoriatic arthritis	0.000329	0.00119	CcSEcCtD
Erlotinib—Syncope—Dexamethasone—psoriatic arthritis	0.000328	0.00118	CcSEcCtD
Erlotinib—Syncope—Betamethasone—psoriatic arthritis	0.000328	0.00118	CcSEcCtD
Erlotinib—Arrhythmia—Prednisone—psoriatic arthritis	0.000327	0.00118	CcSEcCtD
Erlotinib—Infection—Triamcinolone—psoriatic arthritis	0.000327	0.00118	CcSEcCtD
Erlotinib—Infection—Methylprednisolone—psoriatic arthritis	0.000327	0.00118	CcSEcCtD
Erlotinib—Shock—Triamcinolone—psoriatic arthritis	0.000324	0.00117	CcSEcCtD
Erlotinib—Insomnia—Prednisolone—psoriatic arthritis	0.000324	0.00117	CcSEcCtD
Erlotinib—Alopecia—Prednisone—psoriatic arthritis	0.000324	0.00117	CcSEcCtD
Erlotinib—Shock—Methylprednisolone—psoriatic arthritis	0.000323	0.00117	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000323	0.00116	CcSEcCtD
Erlotinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000322	0.00116	CcSEcCtD
Erlotinib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000322	0.00116	CcSEcCtD
Erlotinib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000322	0.00116	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000322	0.00116	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—psoriatic arthritis	0.000321	0.00116	CcSEcCtD
Erlotinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000319	0.00115	CcSEcCtD
Erlotinib—Erythema—Prednisone—psoriatic arthritis	0.000319	0.00115	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—psoriatic arthritis	0.000319	0.00115	CcSEcCtD
Erlotinib—Myalgia—Dexamethasone—psoriatic arthritis	0.000312	0.00112	CcSEcCtD
Erlotinib—Myalgia—Betamethasone—psoriatic arthritis	0.000312	0.00112	CcSEcCtD
Erlotinib—Anxiety—Dexamethasone—psoriatic arthritis	0.000311	0.00112	CcSEcCtD
Erlotinib—Anxiety—Betamethasone—psoriatic arthritis	0.000311	0.00112	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000308	0.00111	CcSEcCtD
Erlotinib—Pain—Prednisolone—psoriatic arthritis	0.000306	0.0011	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—psoriatic arthritis	0.000306	0.0011	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000306	0.0011	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000302	0.00109	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.0003	0.00108	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.0003	0.00108	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000299	0.00108	CcSEcCtD
Erlotinib—Oedema—Dexamethasone—psoriatic arthritis	0.000299	0.00108	CcSEcCtD
Erlotinib—Oedema—Betamethasone—psoriatic arthritis	0.000299	0.00108	CcSEcCtD
Erlotinib—Insomnia—Triamcinolone—psoriatic arthritis	0.000298	0.00107	CcSEcCtD
Erlotinib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000297	0.00107	CcSEcCtD
Erlotinib—Infection—Dexamethasone—psoriatic arthritis	0.000297	0.00107	CcSEcCtD
Erlotinib—Infection—Betamethasone—psoriatic arthritis	0.000297	0.00107	CcSEcCtD
Erlotinib—Shock—Dexamethasone—psoriatic arthritis	0.000294	0.00106	CcSEcCtD
Erlotinib—Shock—Betamethasone—psoriatic arthritis	0.000294	0.00106	CcSEcCtD
Erlotinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000294	0.00106	CcSEcCtD
Erlotinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000293	0.00106	CcSEcCtD
Erlotinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000293	0.00106	CcSEcCtD
Erlotinib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000293	0.00106	CcSEcCtD
Erlotinib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000293	0.00106	CcSEcCtD
Erlotinib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00029	0.00105	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000289	0.00104	CcSEcCtD
Erlotinib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000289	0.00104	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—psoriatic arthritis	0.000286	0.00103	CcSEcCtD
Erlotinib—Syncope—Prednisone—psoriatic arthritis	0.000286	0.00103	CcSEcCtD
Erlotinib—Anorexia—Dexamethasone—psoriatic arthritis	0.000285	0.00103	CcSEcCtD
Erlotinib—Anorexia—Betamethasone—psoriatic arthritis	0.000285	0.00103	CcSEcCtD
Erlotinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000284	0.00102	CcSEcCtD
Erlotinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000283	0.00102	CcSEcCtD
Erlotinib—Pain—Triamcinolone—psoriatic arthritis	0.000282	0.00102	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—psoriatic arthritis	0.00028	0.00101	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000276	0.000995	CcSEcCtD
Erlotinib—Chills—Methotrexate—psoriatic arthritis	0.000275	0.000991	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000272	0.000982	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000272	0.000982	CcSEcCtD
Erlotinib—Myalgia—Prednisone—psoriatic arthritis	0.000272	0.000979	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—psoriatic arthritis	0.000272	0.000979	CcSEcCtD
Erlotinib—Anxiety—Prednisone—psoriatic arthritis	0.000271	0.000976	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—psoriatic arthritis	0.000271	0.000976	CcSEcCtD
Erlotinib—Insomnia—Dexamethasone—psoriatic arthritis	0.00027	0.000975	CcSEcCtD
Erlotinib—Insomnia—Betamethasone—psoriatic arthritis	0.00027	0.000975	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00027	0.000973	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000269	0.00097	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—psoriatic arthritis	0.000268	0.000968	CcSEcCtD
Erlotinib—Erythema—Methotrexate—psoriatic arthritis	0.000267	0.000962	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000267	0.000962	CcSEcCtD
Erlotinib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000263	0.000949	CcSEcCtD
Erlotinib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000263	0.000949	CcSEcCtD
Erlotinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00026	0.000939	CcSEcCtD
Erlotinib—Oedema—Prednisone—psoriatic arthritis	0.00026	0.000939	CcSEcCtD
Erlotinib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00026	0.000937	CcSEcCtD
Erlotinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.00026	0.000937	CcSEcCtD
Erlotinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00026	0.000937	CcSEcCtD
Erlotinib—Infection—Prednisone—psoriatic arthritis	0.000259	0.000933	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000258	0.000931	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000258	0.000931	CcSEcCtD
Erlotinib—Back pain—Methotrexate—psoriatic arthritis	0.000258	0.00093	CcSEcCtD
Erlotinib—Fatigue—Betamethasone—psoriatic arthritis	0.000258	0.00093	CcSEcCtD
Erlotinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000258	0.00093	CcSEcCtD
Erlotinib—Shock—Prednisone—psoriatic arthritis	0.000256	0.000924	CcSEcCtD
Erlotinib—Pain—Dexamethasone—psoriatic arthritis	0.000256	0.000922	CcSEcCtD
Erlotinib—Pain—Betamethasone—psoriatic arthritis	0.000256	0.000922	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000255	0.000921	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—psoriatic arthritis	0.000253	0.000912	CcSEcCtD
Erlotinib—Anorexia—Prednisone—psoriatic arthritis	0.000248	0.000895	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000244	0.000882	CcSEcCtD
Erlotinib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000244	0.000882	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000237	0.000855	CcSEcCtD
Erlotinib—Dizziness—Prednisolone—psoriatic arthritis	0.000237	0.000854	CcSEcCtD
Erlotinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000236	0.000853	CcSEcCtD
Erlotinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000236	0.000852	CcSEcCtD
Erlotinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000236	0.000852	CcSEcCtD
Erlotinib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000236	0.000852	CcSEcCtD
Erlotinib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000236	0.000852	CcSEcCtD
Erlotinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000236	0.000851	CcSEcCtD
Erlotinib—Insomnia—Prednisone—psoriatic arthritis	0.000235	0.000849	CcSEcCtD
Erlotinib—Pruritus—Triamcinolone—psoriatic arthritis	0.000233	0.000841	CcSEcCtD
Erlotinib—Cough—Methotrexate—psoriatic arthritis	0.000233	0.000839	CcSEcCtD
Erlotinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000233	0.000839	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—psoriatic arthritis	0.000229	0.000827	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—psoriatic arthritis	0.000227	0.000819	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—psoriatic arthritis	0.000227	0.000819	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—psoriatic arthritis	0.000227	0.000819	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000226	0.000816	CcSEcCtD
Erlotinib—Rash—Prednisolone—psoriatic arthritis	0.000226	0.000815	CcSEcCtD
Erlotinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000226	0.000814	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000225	0.000813	CcSEcCtD
Erlotinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000225	0.000811	CcSEcCtD
Erlotinib—Fatigue—Prednisone—psoriatic arthritis	0.000224	0.00081	CcSEcCtD
Erlotinib—Headache—Prednisolone—psoriatic arthritis	0.000224	0.000809	CcSEcCtD
Erlotinib—Constipation—Prednisone—psoriatic arthritis	0.000223	0.000803	CcSEcCtD
Erlotinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000218	0.000786	CcSEcCtD
Erlotinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000217	0.000784	CcSEcCtD
Erlotinib—Infection—Methotrexate—psoriatic arthritis	0.000216	0.00078	CcSEcCtD
Erlotinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000214	0.000774	CcSEcCtD
Erlotinib—Asthenia—Betamethasone—psoriatic arthritis	0.000214	0.000774	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000213	0.00077	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000213	0.000768	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000213	0.000768	CcSEcCtD
Erlotinib—Nausea—Prednisolone—psoriatic arthritis	0.000213	0.000768	CcSEcCtD
Erlotinib—Pruritus—Betamethasone—psoriatic arthritis	0.000211	0.000763	CcSEcCtD
Erlotinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000211	0.000763	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000211	0.000762	CcSEcCtD
Erlotinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000209	0.000756	CcSEcCtD
Erlotinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000209	0.000754	CcSEcCtD
Erlotinib—Rash—Triamcinolone—psoriatic arthritis	0.000208	0.000749	CcSEcCtD
Erlotinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000207	0.000749	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—psoriatic arthritis	0.000207	0.000748	CcSEcCtD
Erlotinib—Rash—Methylprednisolone—psoriatic arthritis	0.000207	0.000748	CcSEcCtD
Erlotinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000207	0.000747	CcSEcCtD
Erlotinib—Headache—Triamcinolone—psoriatic arthritis	0.000206	0.000744	CcSEcCtD
Erlotinib—Headache—Methylprednisolone—psoriatic arthritis	0.000206	0.000743	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—psoriatic arthritis	0.000206	0.000742	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000206	0.000742	CcSEcCtD
Erlotinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000204	0.000738	CcSEcCtD
Erlotinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000204	0.000738	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000198	0.000715	CcSEcCtD
Erlotinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000198	0.000713	CcSEcCtD
Erlotinib—Dizziness—Betamethasone—psoriatic arthritis	0.000198	0.000713	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—psoriatic arthritis	0.000197	0.00071	CcSEcCtD
Erlotinib—Nausea—Triamcinolone—psoriatic arthritis	0.000196	0.000706	CcSEcCtD
Erlotinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000195	0.000704	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000194	0.0007	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000191	0.000691	CcSEcCtD
Erlotinib—Vomiting—Dexamethasone—psoriatic arthritis	0.00019	0.000686	CcSEcCtD
Erlotinib—Vomiting—Betamethasone—psoriatic arthritis	0.00019	0.000686	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000189	0.000682	CcSEcCtD
Erlotinib—Rash—Betamethasone—psoriatic arthritis	0.000188	0.00068	CcSEcCtD
Erlotinib—Rash—Dexamethasone—psoriatic arthritis	0.000188	0.00068	CcSEcCtD
Erlotinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000188	0.000679	CcSEcCtD
Erlotinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000188	0.000679	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000188	0.000677	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—psoriatic arthritis	0.000188	0.000677	CcSEcCtD
Erlotinib—Headache—Betamethasone—psoriatic arthritis	0.000187	0.000675	CcSEcCtD
Erlotinib—Headache—Dexamethasone—psoriatic arthritis	0.000187	0.000675	CcSEcCtD
Erlotinib—Asthenia—Prednisone—psoriatic arthritis	0.000187	0.000674	CcSEcCtD
Erlotinib—Pain—Methotrexate—psoriatic arthritis	0.000186	0.000671	CcSEcCtD
Erlotinib—Pruritus—Prednisone—psoriatic arthritis	0.000184	0.000664	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000178	0.000642	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000178	0.000642	CcSEcCtD
Erlotinib—Nausea—Dexamethasone—psoriatic arthritis	0.000178	0.00064	CcSEcCtD
Erlotinib—Nausea—Betamethasone—psoriatic arthritis	0.000178	0.00064	CcSEcCtD
Erlotinib—Dizziness—Prednisone—psoriatic arthritis	0.000172	0.000621	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000172	0.00062	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000172	0.00062	CcSEcCtD
Erlotinib—Vomiting—Prednisone—psoriatic arthritis	0.000165	0.000597	CcSEcCtD
Erlotinib—Rash—Prednisone—psoriatic arthritis	0.000164	0.000592	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—psoriatic arthritis	0.000164	0.000591	CcSEcCtD
Erlotinib—Headache—Prednisone—psoriatic arthritis	0.000163	0.000588	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—psoriatic arthritis	0.000156	0.000563	CcSEcCtD
Erlotinib—Nausea—Prednisone—psoriatic arthritis	0.000155	0.000558	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—psoriatic arthritis	0.000154	0.000555	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000149	0.000537	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—psoriatic arthritis	0.000144	0.000519	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—psoriatic arthritis	0.000138	0.000499	CcSEcCtD
Erlotinib—Rash—Methotrexate—psoriatic arthritis	0.000137	0.000495	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000137	0.000494	CcSEcCtD
Erlotinib—Headache—Methotrexate—psoriatic arthritis	0.000136	0.000492	CcSEcCtD
Erlotinib—Nausea—Methotrexate—psoriatic arthritis	0.000129	0.000466	CcSEcCtD
